We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use iwcll.org, remember your settings and improve our services. We also use cookies set by other sites to help us deliver content from their services.
Thomas Lew, Undetectable Minimal Residual Disease Should be the Goal of Venetoclax Therapy in Relapsed and Refractory Chronic Lymphocytic Leukaemia
Home > Resources > Thomas Lew, Undetectable Minimal Residual Disease Should be the Goal of Venetoclax Therapy in Relapsed and Refractory Chronic Lymphocytic Leukaemia
